Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

Drugs

Volumn 55, Issue 3, 1998, Pages 423-435

  Gunasekara, Nishan S ^a   Faulds, Diana ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; POLYGLUTAMIC ACID; RALTITREXED; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; AREA UNDER THE CURVE; ASTHENIA; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DRUG COST; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSPORT; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MUCOSA INFLAMMATION; NAUSEA; QUALITY OF LIFE; REVIEW; URINARY EXCRETION; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FOLIC ACID ANTAGONISTS; HUMANS; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE;

EID: 0031915084     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199855030-00012     Document Type: Review

References (44)

1. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991 Oct 15; 51: 5579-86
2. Jackman AL, Gibson W, Brown M, et al. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol 1993; 339: 265-76
3. Gibson W, Bisset GMF, Marsham PR, et al. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells. Biochem Pharmacol 1993; 45 (4): 863-9
4. Jackman AL, Marsham PR, Moran RG, et al. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates. Adv Enzyme Regul 1991; 31: 13-27
5. Ward WHJ, Kimbell R, Jackman AL. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol 1992 May 8; 43: 2029-31
6. Jackman AL, Kelland LR, Kimbell R, et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 1995 May; 71: 914-24
7. Jackman AL, Farrugia DC, Gibson W, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer A 1995 Jul-Aug; 31A: 1277-82
8. Jackman AL, Boyle FT, Harrap KR. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Invest New Drugs 1996; 14 (3): 305-16
9. Jackman AL, Kimbell R, Brunton L, et al. Tomudex (ZD1694): a specific inhibitor of thymidylate synthase designed to overcome resistance to the non-specific inhibitor, 5-fluorouracil [abstract]. Ann Oncol 1996; 7 Suppl. 1: 88
10. Chang YM, Zielinski Z, Izzo J, et al. Pretreatment of colon carcinoma cells to D1694 (Tomudex) markedly enhances 5-fluorouracil cytotoxicity [abstract]. Proc Am Assoc Cancer Res 1994 Mar; 35: 330
11. Harstrick A, Schleucher N, Gonzales A, et al. Interactions and cross resistance patterns between various schedules of 5-FU and the new, folate-based thymidilate synthase inhibitor Tomudex (D1694). Eur J Cancer 1995 Oct 30; 31A Suppl. 5: S30
12. Aschele C, Sobrero A, Baldo C, et al. In vitro synergism between SN-38 and Tomudex: importance of scheduling and dose ratio [abstract]. Ann Oncol 1996; 7 Suppl. 5: 129
13. Kimbell R, Jackman AL. In vitro studies with ZD1694 (Tomudex) and SN38 in human colon tumour cell lines: chemistry and biology of pteridines and folates 1997. Proceedings of the Eleventh International Symposium on Pteridines and Folates; 1997 Jun 15-20; Berchtesgaden
14. Harstrick A, Schleucher N, Vanhoefer U, et al. Cytotoxic interactions of SN38, the active metabolite of irinotecan, and 5-FU or tomudex in 5-FU sensitive and 5-FU resistant colorectal carcinoma cell lines [abstract]. Ann Oncol 1996; 7 Suppl. 5: 5
15. Stephens TC, Smith MN, Waterman SE, et al. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors. Adv Exp Med Biol 1993; 338: 589-92
16. Stephens TC, Calvete JA, Janes D, et al. Antitumour activity of a new thymidylate synthase inhibitor, D1694 [abstract]. Proc Am Assoc Cancer Res 1990 Mar; 31: 342
17. Jackman AL, Jodrell DI, Gibson W, et al. ICI D1694, an inhibitor of thymidylate synthase for clinical study. Adv Exp Med Biol 1991; 309A: 19-23
18. Stephens TC, Valcaccia BE, Sheader ML, et al. The thymidylate synthase inhibitor ICI D1694 is superior to CB37I7, 5-fluorouracil (5-FU) and methotrexate (MIX) against a panel of human tumour xenografts [abstract]. Proc Am Assoc Cancer Res 1991 Mar; 32: 328
19. Clarke SJ, Hanwell J, de Boer M, et al. Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996 May; 14: 1495-503
20. Judson IR, Aherne GW, Maughan T, et al. Pharmacokinetic studies with Tomudex (ZD1694) [abstract]. Ann Oncol 1996; 7 Suppl. 1: 88
21. Judson IR. 'Tomudex' (raltitrexed) development: preclinical, phase I and II studies. Anticancer Drugs 1997; 8 Suppl. 2: S5-9
22. Zalcberg JR, Cunningham D, Van Cutsem E, et al. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996 Mar; 14: 716-21
23. Cunningham D, Zalcberg JR, Rath U, et al. Final results of a randomised trial comparing Tomudex (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann Oncol 1996 Nov; 7: 961-5
24. Cocconi G. Results of a European multicentre trial of Tumodex versus 5-FU/high dose LV (Machover regimen). Tumori 1997 Jan-Feb; 83 Suppl.: S72
25. Pazdur R, Vincent M. Raltitrexed (Tomudex) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter, North American trial [abstract no. 801]. Proc Am Soc Clin Oncol 1997 17-20 May; 16: 228a
26. Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94
27. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981 Jan 1; 47: 207-14
28. Kerr DJ. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer. Anticancer Drugs 1997; 8 Suppl. 2: S11-5
29. Zalcberg J. Overview of the tolerability of 'Tomudex' (raltitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs 1997; 8 Suppl. 2: S17-22
30. Zeneca, London, 1998. (Data on file)
31. Sorensen JM, Jordan E, Grem JL, et al. Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase [abstract]. Ann Oncol 1994; 5 Suppl. 5: 132
32. Ross P, Heron J, Cunningham D. Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer A 1996; 32A Suppl. 5: S13-17
33. Summerhayes M, Wanklyn SJ, Shakespeare RA, et al. Reduced pharmacy resource utilization associated with raltitrexed treatment of advanced colorectal cancer. J Oncol Pharm Practice 1997; 3(1): 24-30
34. Kerr DJ, O'Connor KM. The costs of managing advanced colorectal cancer: a broad perspective. Anticancer Drugs 1997; 8 Suppl. 2: S23-6
35. Elliott R. An analysis of drug costs for the management of chemotherapy-related side effects in advanced colorectal cancer. J Oncol Pharm Practice 1996; 2 (3): 186-90
36. Cunningham D, Zalcherg JR, Rath U, et al. Tomudex (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A (12): 1945-54
37. Wingo P, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995 Jan/Feb; 45 (1): 8-30
38. Estève J, Kricker A, Ferlay J, et al. Facts and figures of cancer in the European Community. Lyon: International Agency for Research on Cancer, 1993
39. Boring CC, Squires TS, Tong T, et al. Cancer statistics, 1994. CA Cancer J Clin 1994 Jan/Feb; 44 (1): 7-26
40. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994 Apr 21; 330 (16): 1136-42
41. Labianca R, Pessi MA, Zamparelli G. Treatment of colorectal cancer: current guidelines and future prospects for drug therapy. Drugs 1997 Apr; 53 (4): 593-607
42. van Triest B, van Groeningen CJ, Pinedo HM. Current chemotherapeutic possibilities in the treatment of colorectal cancer. Eur J Cancer A 1995 Jul-Aug; 31A: 1193-7
43. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-5
44. Van Cutsem E. Future developments with 'Tomudex' (raltitrexed). Anticancer Drugs 1997; 8 Suppl. 2: S33-8